Ductus Arteriosus, Patent Clinical Trial
— NNP-MULTIMODALOfficial title:
Analysis of the Impact of Patent Ductus Arteriosus on Brain Function in Preterm Neonates: Multimodal Approach Integrating EEG-NIRS, Ultrasound and Clinical Data
Verified date | August 2018 |
Source | Centre Hospitalier Universitaire, Amiens |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This project corresponds to the main field of research of the investigators's laboratory
concerning analysis of cerebral electrometabolic and haemodynamic activity in neonates. In
this context, the investigators have developed know-how and specific acquisition and analysis
tools (2 patents and several publications), allowing them to apply this know-how in children
with patent ductus arteriosus.
Patent ductus arteriosus after birth is characterized by shunting of a variable proportion of
cardiac output towards the pulmonary circulation. The direct consequences of this shunting
are: (i) overload of the pulmonary vasculature and left heart chambers, increasing the risk
of left heart failure, haemorrhagic pulmonary oedema and late respiratory complications such
as bronchopulmonary dysplasia; (ii) in contrast with the pulmonary circulation, other
systemic organs are deprived of part of their normal perfusion and are subject to ischaemic
hypoxia; the resulting neuronal hypoxia rapidly leads to metabolic and electrical
dysfunction, the analysis of which constitutes one of the objectives of this project.
Status | Completed |
Enrollment | 51 |
Est. completion date | February 2017 |
Est. primary completion date | February 2017 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | N/A to 1 Day |
Eligibility |
Inclusion Criteria: 1. Group of children : - meeting the age criteria - having a ductus arteriosus persistence. 2. Group of children : - meeting the age criteria - with persistent ductus arteriosus in the ultrasound examination - for which a cardiac or respiratory treatment has already been put in place. 3. normal group of children : - meeting the age criteria - without ductus arteriosus persistence ultrasound or detectable neurological disorders after clinical, neurophysiological and radiological (ETF , Scanner, MRI). Exclusion Criteria: |
Country | Name | City | State |
---|---|---|---|
France | CHU Amiens | Amiens |
Lead Sponsor | Collaborator |
---|---|
Centre Hospitalier Universitaire, Amiens |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | change in cerebral tissue oxygenation | Day 3, Day 5 , Day 12, week 5 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT03604796 -
Alternative Paracetamol Treatments for the Neonate With a hsPDA
|
Phase 2/Phase 3 | |
Completed |
NCT00000494 -
Management of Patent Ductus in Premature Infants
|
Phase 3 | |
Completed |
NCT01251939 -
Changes in Renal and Splanchnic Oxygenation During Ibuprofen Treatment for Patent Ductus Arterious
|
N/A | |
Completed |
NCT01031316 -
Patent Ductus Arteriosus (PDA) Screening Trial
|
N/A | |
Completed |
NCT00828334 -
NIT-OCCLUD PDA Phase II Sentinel Trial
|
N/A | |
Completed |
NCT00009646 -
Trial of Indomethacin Prophylaxis in Preterm Infants (TIPP)
|
Phase 3 | |
Withdrawn |
NCT00470743 -
Comparing Ibuprofen And Indomethacin For The Treatment Of The Patent Ductus Arteriosus in Very Premature Babies
|
Phase 4 | |
Completed |
NCT00725647 -
Plasma N-terminal proBNP Concentrations and Patent Ductus Arteriosus in Preterm Babies
|
N/A | |
Terminated |
NCT00239512 -
New Management Strategy of PDA for VLBW Preterm Infants
|
N/A | |
Recruiting |
NCT04508036 -
Ductus Arteriosus Closure and D-Dimer and Fibrinogen Levels
|
||
Completed |
NCT01243996 -
High-dose Ibuprofen for Patent Ductus Arteriosus (PDA) in Preterm Infant
|
Phase 2/Phase 3 | |
Completed |
NCT00005190 -
Reproduction and Survival After Cardiac Defect Repair
|
N/A | |
Not yet recruiting |
NCT04205877 -
The U.S. PDA Registry
|
||
Recruiting |
NCT05547165 -
Percutaneous Intervention Versus Observational Trial of Arterial Ductus in Low Weight Infants
|
N/A | |
Completed |
NCT02422966 -
Paracetamol in Patent Ductus Arteriosus
|
Phase 2 | |
Completed |
NCT00799123 -
Urine NT-proBNP Levels and Echocardiographic Findings in Very Low Birth Weight (VLBW) Infants
|
N/A | |
Completed |
NCT00528736 -
Plasma B-Type Natriuretic Peptide Concentrations in Preterm Infants < 28 Weeks
|
N/A | |
Completed |
NCT02002741 -
Adding Paracetamol to Ibuprofen for Treatment of Patent Ductus Arteriosus in Preterm Infants
|
Phase 2/Phase 3 |